All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Peptide therapy TikTok claims: what the science actually supports

Alexandra Jaye Weinstein

TikTok creator

4.4K viewsWatch on TikTok→

Quick answer

The creator discontinued prescription ADHD medication and initiated NAD+ supplementation on her own, reporting acute subjective improvements in energy and mood within 15 to 20 minutes of her first dose. There are no published randomized controlled trials demonstrating NAD+ supplementation as an effective treatment for ADHD, and the rapid onset she describes is inconsistent with known pharmacokinetics for oral NAD+ precursors, pointing toward expectancy effects. Discontinuing evidence-based ADHD treatment without clinical supervision carries documented risks including symptom rebound, impaired functioning, and delayed access to effective care.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.

What did @alexandrajaye5 actually say?

She stopped her ADHD medication and started exploring peptides as an alternative. A friend pointed her toward NAD+ first, and on day one she reported feeling "fucking fantastic" within 15 to 20 minutes, describing a burst of clean energy, happiness, and no anxiety. She's planning to dose up from 25 to 50 units over two weeks.

To be clear about what this video is: a single person, one dose in, reporting how she feels. That's an anecdote, not evidence. The enthusiasm is real and relatable. The conclusions she's drawing from it, however, are running way ahead of the data. And the part where she stopped a prescription medication to try supplements instead is where this gets genuinely concerning from a clinical standpoint.

Does the science back this up?

There is real and growing research on NAD+ precursors, particularly nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), for cellular energy metabolism and mitochondrial function. What there is not, as of now, is solid clinical evidence that NAD+ supplementation reliably treats ADHD symptoms in adults.

The mechanistic logic isn't crazy. NAD+ plays a role in dopamine synthesis pathways, and dopamine dysregulation is central to ADHD. Braidy et al. (2019, Antioxidants and Redox Signaling) documented NAD+'s role in neuronal function, but that's a long way from "this replaces Adderall." A 2023 review in Neuropsychopharmacology found no randomized controlled trials specifically testing NAD+ supplementation for ADHD. The energy boost she felt is plausible, possibly from increased mitochondrial activity, but the 15-to-20-minute window she describes is faster than most pharmacokinetic models would predict for oral supplementation, which suggests placebo response is doing some of the heavy lifting here.

What did they get wrong (or right)?

She gets partial credit for one thing: approaching this incrementally. Starting low and building up is reasonable harm-reduction thinking, even if "25 units" as a dosing description is vague enough to be nearly meaningless without knowing the product concentration and delivery method.

What she gets wrong is the implication that day-one subjective feelings are a meaningful signal about long-term efficacy. They aren't. The placebo effect on energy and mood can be substantial, especially on day one of something you're excited about. Geers et al. (2019, Health Psychology) demonstrated that expectancy effects alone can produce measurable physiological changes. She's essentially describing textbook expectancy response: anticipation, rapid perceived onset, and mood elevation.

More seriously, stopping ADHD medication without medical supervision to try an unregulated supplement is not a neutral decision. ADHD medications have established efficacy profiles backed by decades of controlled trials. NAD+ does not have that evidence base for this indication. Presenting this as a potential "really great solution" for ADHD, on day one, is misleading to her audience even if she doesn't intend it that way.

What should you actually know?

NAD+ supplementation is not a fraud. There's legitimate science behind its role in aging, mitochondrial health, and neuroprotection. Yoshino et al. (2021, Science) showed NMN improved insulin sensitivity and muscle function in older women, which is promising but not ADHD-specific. The compound has a real research track record in longevity and metabolic contexts.

For ADHD specifically, the evidence gap is significant. No peer-reviewed trial has demonstrated that NAD+ supplementation reduces core ADHD symptoms like inattention or executive dysfunction at clinically meaningful levels. Anyone watching this and thinking about swapping their medication for NAD+ should have that conversation with a prescriber first, not after a TikTok rabbit hole.

The other thing worth flagging: the term "units" for dosing NAD+ is nonstandard. NAD+ is typically dosed in milligrams. If she's using an injectable formulation, "units" could mean something specific to that product, but without context it's impossible to evaluate whether her dose is physiologically meaningful at all.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

Peptide social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 9 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For Peptide therapy TikTok claims: what the science actually supports, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Peptide therapy TikTok claims: what the science actually supports is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

Compare providers, services and access requirements in the directory before contacting a suitable care team.

Claim verdict

The useful answer behind this video

Claim being checked

The creator discontinued prescription ADHD medication and initiated NAD+ supplementation on her own, reporting acute subjective improvements in energy and mood within 15 to 20 minutes of her first dose.

FormBlends verdict

The creator discontinued prescription ADHD medication and initiated NAD+ supplementation on her own, reporting acute subjective improvements in energy and mood within 15 to 20 minutes of her first dose. There are no published randomized controlled trials demonstrating NAD+ supplementation as an effective treatment for ADHD, and the rapid onset she describes is inconsistent with known pharmacokinetics for oral NAD+ precursors, pointing toward expectancy effects. Discontinuing evidence-based ADHD treatment without clinical supervision carries documented risks including symptom rebound, impaired functioning, and delayed access to effective care.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The creator discontinued prescription ADHD medication and initiated NAD+ supplementation on her own, reporting acute subjective improvements in energy and mood within 15 to 20 minutes of her first dose. There are no published randomized controlled trials demonstrating NAD+ supplementation as an effective treatment for ADHD, and the rapid onset she describes is inconsistent with known pharmacokinetics for oral NAD+ precursors, pointing toward expectancy effects. Discontinuing evidence-based ADHD treatment without clinical supervision carries documented risks including symptom rebound, impaired functioning, and delayed access to effective care.
  • No randomized controlled trials have tested NAD+ supplementation specifically for ADHD, per a 2023 Neuropsychopharmacology review.
  • A 15-to-20-minute subjective onset after oral NAD+ is faster than pharmacokinetic models support, suggesting expectancy effects are likely contributing.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • No randomized controlled trials have tested NAD+ supplementation specifically for ADHD, per a 2023 Neuropsychopharmacology review.
  • A 15-to-20-minute subjective onset after oral NAD+ is faster than pharmacokinetic models support, suggesting expectancy effects are likely contributing.
  • Geers et al. (2019, Health Psychology) showed expectancy alone can produce measurable physiological changes in energy and mood, which is relevant here.
  • Yoshino et al. (2021, Science) found NMN improved metabolic markers in older adults, but those findings do not extend to ADHD symptom management.
  • Stopping prescription ADHD medication without clinical supervision carries documented risks including symptom rebound and impaired daily functioning.
  • NAD+ is measured in milligrams in clinical research; dosing described in 'units' without product context cannot be evaluated for physiological relevance.
  • NAD+ has a legitimate research profile in longevity and mitochondrial health, but that does not make it an evidence-based ADHD treatment.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Alexandra Jaye Weinstein · TikTok creator

4.4K views on this video

Peptide therapy TikTok claims: what the science actually supports

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Alexandra Jaye Weinstein, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.